Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 10;5(6):e003323. doi: 10.1161/JAHA.116.003323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Mean free PCSK9 levels in all 3 treatment groups (A), and free PCSK9 levels compared with percentage changes in LDL‐C from the main baseline (day −29) for alirocumab plus placebo (B), plus ezetimibe (C), and plus fenofibrate (D). Dotted lines between days 29 and 57 indicate no measurement taken for this period. EZE indicates ezetimibe; FENO, fenofibrate; LDL‐C, low‐density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin 9; Q4W, every 4 weeks.